edp-788
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2014 (NCT01999725)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- SARS-CoV-2INHIBITOR
SARS-CoV-2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- edp-788
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02255968 | Phase 1 | Aug 1, 2014 | Enanta Pharmaceuticals |
| NCT01999725 | Phase 1 | Jan 1, 2014 | Enanta Pharmaceuticals, PPD |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals | For profit | 2 | 2 | 1 | 2014 |
| PPD | For profit | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1